915771-74-3

Upstream product

• 915770-55-7 3-chloro-2,4-difluoro-N-(2-hydroxyethyl)-N-methyl-benzamide 
• 54915-31-0 methyl 3-(benzyloxy)-5-hydroxybenzoate 
• 100-39-0 benzyl bromide 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 157373-00-7 3-chloro-2,4-difluoro-benzoyl chloride 
• 67-56-1 methanol 

Downstream Products

• 915771-73-2 methyl 3-hydroxy-5-[(4-methyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-8-yl)oxy]benzoate 
• 915771-78-7 methyl 3-[(1-methylethyl)oxy]-5-[(4-methyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-8-yl)oxy]benzoate 
• 915771-79-8 1-methylethyl 3-[(1-methylethyl)oxy]-5-[(4-methyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-8-yl)oxy]benzoate 
• 915771-76-5 1,1-dimethylethyl 3-[({3-[(1-methylethyl)oxy]-5-[(4-methyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-8-yl)oxy]phenyl}carbonyl)amino]-1H-pyrazole-1-carboxylate 

Relevant academic research and scientific papers

HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES

Compounds of formula (I), wherein R1, R4, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.